Dave Shelton at Pfizer to speak about NGF Inhibitors for Pain on Sept 13-14, 2012 San Francisco, CA
Dave Shelton, Senior Director at Pfizer Global Research & Development will give a featured presentation about NGF Inhibitors for Pain at the Pain Research and Therapeutics Conference (Sept 13-14, 2012 in San Francisco, CA).
- San Francisco, CA (1888PressRelease) July 25, 2012 - Dave Shelton, Senior Director at Pfizer Global Research & Development will give a featured presentation on "Update on Clinical Development of NGF Inhibitors for Pain" at the Pain Research and Therapeutics Conference taking place on Sept 13-14, 2012 in San Francisco, CA.
Chronic Pain has been clinically diagnosed in 40 million people in the United States alone. Over the counter analgesics for chronic pain include non steroidal anti-inflammatories (NSAIDs) and opioids. The analgesic potency of these drugs is very limited and the side effects can include gastrointestinal bleeding and ulceration and renal toxicity, drowsiness/sedation, nausea and vomiting, constipation and the potential for abuse and dependence.
Pfizer has been working on an exciting, newly developed modulator of pain that does not fall into the category of NSAIDs or opioids and their side effects, called Nerve Growth Factor (NGF) Inhibitors. NGF is a cytokine that binds to receptors on peripheral sensory neurons and sensitizes these neurons and lowers pain threshold. In his presentation, Dr. Shelton will provide an update on the clinical development of NGF Inhibitors for pain.
GTC's Pain Research and Therapeutics will discuss the latest breakthroughs, new drug targets, therapeutic approaches, preclinical and clinical development, animal models, beyond traditional opioids, overcoming challenges in pain therapeutics, and much more. The conference is also a part of the 2nd CNS Diseases World Summit. The Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partnering and deal-making.
Join colleagues at this exciting Pain Therapeutics conference and CNS summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Stephen Brannan - VP at Takeda, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, David Shelton at Pfizer, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, Michael C. Venuti - CSO at NeuroTherapeutics, and many more!
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam